The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies

Abstract

In the last decades, progresses in medical oncology have ameliorated the treatment of patients and their outcome. However, further improvements are still necessary, in particular for certain types of tumors such as pancreatic, gastric, and lung cancer as well as acute myeloid leukemia where early detection and monitoring of the disease are crucial for final patient outcome. Liquid biopsy represents a great advance in the field because it is less invasive, less time-consuming, and safer compared to classical biopsies and it can be useful to monitor the evolution of the disease as well as the response of patients to therapy. Liquid biopsy allows the detection of circulating tumor cells, nucleic acids, and exosomes not only in blood but also in different biological fluids: urine, saliva, pleural effusions, cerebrospinal fluid, and stool. Among the potential biomarkers detectable in liquid biopsies, microRNAs (miRNAs) are gaining more and more attention, since they are easily detectable, quite stable in biological fluids, and show high sensitivity. Many data demonstrate that miRNAs alone or in combination with other biomarkers could improve the diagnostic and prognostic power for many different tumors. Despite this, standardization of methods, sample preparation, and analysis remain challenging and a huge effort should be made to address these issues before miRNA biomarkers can enter the clinic. This review summarizes the main findings in the field of circulating miRNAs in both solid and hematological tumors.

Keywords

MicroRNAs / liquid biopsies / diagnosis / prognosis / therapy

References

[1] Reckamp KL,Karlovich C,Camidge DR.A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma..J Thorac Oncol2016;11:1690-700

[2] Wang Y,Mulvey CL,Schaefer J.Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas..Sci Transl Med2015;7:293ra104 PMCID:PMC4587492

[3] Kimura H,Sone T,Tamura T.EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib..Br J Cancer2006;95:1390-5 PMCID:PMC2360588

[4] De Mattos-Arruda L,Ng CKY,Martinez-Ricarte F.Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma..Nat Commun2015;6:8839 PMCID:PMC5426516

[5] Diehl F,Durkee KH,Goodman SN.Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients..Gastroenterology2008;135:489-98 PMCID:PMC2820386

[6] Lianidou E.Liquid biopsies..Genes Chromosomes Cancer2019;58:219-32

[7] Siravegna G,Siena S.Integrating liquid biopsies into the management of cancer..Nat Rev Clin Oncol2017;14:531-48

[8] Pantel K.Real-time liquid biopsy in cancer patients: fact or fiction?.Cancer Res2013;73:6384-8

[9] Xi L,Spurgeon S,Gong H.New library construction method for single-cell genomes..PLoS One2017;12:e0181163 PMCID:PMC5517011

[10] Lawrie CH,Dunlop HM,Liggins AP.Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma..Br J Haematol2008;141:672-5

[11] Mitchell PS,Kroh EM,Wyman SK.Circulating microRNAs as stable blood-based markers for cancer detection..Proc Natl Acad Sci U S A2008;105:10513-8 PMCID:PMC2492472

[12] Lee RC,Ambros V.The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14..Cell1993;75:843-54

[13] Li SC,Hu LY,Hsu CN.Identification of homologous microRNAs in 56 animal genomes..Genomics2010;96:1-9

[14] Friedlander MR,Houben AJ,Banez-Coronel M.Evidence for the biogenesis of more than 1,000 novel human microRNAs..Genome Biol2014;15:R57 PMCID:PMC4054668

[15] Bartel DP.MicroRNAs: genomics, biogenesis, mechanism, and function..Cell2004;116:281-97

[16] Tan W,Qu S,Luo W.MicroRNAs and cancer: key paradigms in molecular therapy..Oncol Lett2018;15:2735-42 PMCID:PMC5778870

[17] Chen X,Ma L,Yin Y.Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases..Cell Res2008;18:997-1006

[18] Arroyo JD,Kroh EM,Pritchard CC.Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma..Proc Natl Acad Sci U S A2011;108:5003-8 PMCID:PMC3064324

[19] Cogswell JP,Taylor IA,Shi Y.Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways..J Alzheimers Dis2008;14:27-41

[20] Gallo A,Alevizos I.The majority of microRNAs detectable in serum and saliva is concentrated in exosomes..PLoS One2012;7:e30679 PMCID:PMC3302865

[21] Zhou Q,Wang X,Wang T.Immune-related microRNAs are abundant in breast milk exosomes..Int J Biol Sci2012;8:118-23 PMCID:PMC3248653

[22] Weber JA,Zhang S,Huang KH.The microRNA spectrum in 12 body fluids..Clin Chem2010;56:1733-41 PMCID:PMC4846276

[23] Da Silveira J,Perecin F,Winger QA.Isolation and Analysis of exosomal MicroRNAs from ovarian follicular fluid..Methods Mol Biol2018;1733:53-63

[24] Cote GA,McElyea SD,Xu H.A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile..Am J Gastroenterol2014;109:1942-52 PMCID:PMC4261139

[25] Roman-Canal B,Moiola CP,Bonnin S.EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer..J Transl Med2019;17:208 PMCID:PMC6585099

[26] Shigeyasu K,Zumwalt TJ,Goel A.Emerging role of MicroRNAs as liquid biopsy biomarkers in gastrointestinal cancers..Clin Cancer Res2017;23:2391-9 PMCID:PMC5433899

[27] Vickers KC,Shoucri BM,Remaley AT.MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins..Nat Cell Biol2011;13:423-33 PMCID:PMC3074610

[28] Cortez MA,Ferdin J,Sood AK.MicroRNAs in body fluids--the mix of hormones and biomarkers..Nat Rev Clin Oncol2011;8:467-77 PMCID:PMC3423224

[29] Stark R,Hadfield J.RNA sequencing: the teenage years..Nat Rev Genet2019;20:631-56

[30] Pardini B.MicroRNAs and long non-coding RNAs and their hormone-like activities in cancer..Cancers (Basel)2019;11: PMCID:PMC6468345

[31] Iftikhar H.Evidence and potential in vivo functions for biofluid miRNAs: from expression profiling to functional testing: potential roles of extracellular miRNAs as indicators of physiological change and as agents of intercellular information exchange..Bioessays2016;38:367-78

[32] Chan M,Ji SM,Wong CY.Identification of circulating microRNA signatures for breast cancer detection..Clin Cancer Res2013;19:4477-87

[33] Sochor M,Pesta M,Bartos J.Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum..BMC Cancer2014;14:448 PMCID:PMC4075993

[34] Roth C,Muller V,Pantel K.Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer..Breast Cancer Res2010;12:R90 PMCID:PMC3046429

[35] Heneghan HM,Kelly R,Kerin MJ.Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease..Oncologist2010;15:673-82 PMCID:PMC3228012

[36] Shimomura A,Kawauchi J,Sakamoto H.Novel combination of serum microRNA for detecting breast cancer in the early stage..Cancer Sci2016;107:326-34 PMCID:PMC4814263

[37] Hannafon BN,Calloway CL,Lum DH.Plasma exosome microRNAs are indicative of breast cancer..Breast Cancer Res2016;18:90 PMCID:PMC5016889

[38] Li P,Zhou X,Huang H.Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer..Onco Targets Ther2017;10:5711-8 PMCID:PMC5713693

[39] McAnena P,Curran C,Freedman JE.Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer..BMC Cancer2019;19:436 PMCID:PMC6511137

[40] Tan W,Xie X,Tan L.Incorporating MicroRNA into molecular phenotypes of circulating tumor cells enhances the prognostic accuracy for patients with metastatic breast cancer..Oncologist20191;24:e1044-54 PMCID:PMC6853100

[41] Shao B,Zhang L,Liu X.Plasma microRNAs predict chemoresistance in patients with metastatic breast cancer..Technol Cancer Res Treat2019;18:1533033819828709 PMCID:PMC6383099

[42] Douillard JY,Siena S,Burkes R.Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer..N Engl J Med2013;369:1023-34

[43] Vauthey JN,Kopetz SE,Chen SS.RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases..Ann Surg2013;258:619-26discussion 26-7 PMCID:PMC3856211

[44] Zimmitti G,Mise Y,Loyer EM.RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases..Ann Surg Oncol2015;22:834-42 PMCID:PMC4318708

[45] Choi HH,Choi JH,Kim SS.Stool-Based miR-92a and miR-144* as Noninvasive Biomarkers for Colorectal Cancer Screening..Oncology2019;97:173-9

[46] Yau TO,Harriss EK,Polytarchou C.Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: a meta-analysis..Sci Rep2019;9:9491 PMCID:PMC6603164

[47] Link A,Shen Y,Lozano JJ.Fecal MicroRNAs as novel biomarkers for colon cancer screening..Cancer Epidemiol Biomarkers Prev2010;19:1766-74 PMCID:PMC2901410

[48] Zhu M,Zhu D,Shan X.A panel of microRNA signature in serum for colorectal cancer diagnosis..Oncotarget2017;8:17081-91 PMCID:PMC5370024

[49] Wikberg ML,Palmqvist R,Ljuslinder I.Plasma miRNA can detect colorectal cancer, but how early?.Cancer Med2018;7:1697-705 PMCID:PMC5943420

[50] Zanutto S,Ghilotti M,Ravagnani F.Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer..Br J Cancer2014;110:1001-7 PMCID:PMC3929896

[51] Wang S,Li Z,Hu J.A plasma microRNA panel for early detection of colorectal cancer..Int J Cancer2015;136:152-61

[52] Zanutto S,Belfiore A,Masci E.Plasma miRNA-based signatures in CRC screening programs..Int J Cancer2020;146:1164-73

[53] Karimi N,Safaralizadeh R,Baradaran B.Serum overexpression of miR-301a and miR-23a in patients with colorectal cancer..J Chin Med Assoc2019;82:215-20

[54] Pesta M,Topolcan O,Houfkova K.Plasma microRNA levels combined with CEA and CA19-9 in the follow-up of colorectal cancer patients..Cancers (Basel)2019;11: PMCID:PMC6627112

[55] Cheng H,Cogdell DE,Schetter AJ.Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis..PLoS One2011;6:e17745 PMCID:PMC3060165

[56] Ji D,Yao Y,Chen H.Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients..EBioMedicine2018;35:189-97 PMCID:PMC6156709

[57] Wagner AD,Haerting J,Grothey A.Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data..J Clin Oncol2006;24:2903-9

[58] Feng F,Xu G,Liu S.Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer..BMC Cancer2017;17:737 PMCID:PMC5679342

[59] Cai H,Hao YF,Wei X.Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer..Med Oncol2013;30:452

[60] Zhu XL,Wang HP,Zhang L.Plasma microRNAs as potential new biomarkers for early detection of early gastric cancer..World J Gastroenterol2019;25:1580-91 PMCID:PMC6452233

[61] Wu J,Wang Z,Chen R.Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer..Dis Markers2015;2015:435656 PMCID:PMC4433679

[62] Liu R,Hu Z,Wang C.A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis..Eur J Cancer2011;47:784-91

[63] Liu H,Liu B,Meng X.Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer..Cancer Lett2012;316:196-203

[64] Han X,Zhao H,Sun B.Serum miR-515-3p, a potential new RNA biomarker, is involved in gastric carcinoma..J Cell Biochem2019;120:15834-43

[65] Wang T,Tian J,Wei R.Low expression levels of plasma miR-141 are associated with susceptibility to gastric cancer..Oncol Lett2019;18:629-36 PMCID:PMC6546987

[66] Hung PS,Chen WT,Fang WL.miR-376c promotes carcinogenesis and serves as a plasma marker for gastric carcinoma..PLoS One2017;12:e0177346 PMCID:PMC5423644

[67] Iwasaki H,Yamada T,Natsume M.A novel urinary microRNA biomarker panel for detecting gastric cancer..J Gastroenterol2019;54:1061-9

[68] Li X,Zhang Y,Wu K.Survival prediction of gastric cancer by a seven-microRNA signature..Gut2010;59:579-85

[69] Tsai MM,Tsai CY,Lee KF.Circulating microRNA-196a/b are novel biomarkers associated with metastatic gastric cancer..Eur J Cancer2016;64:137-48

[70] Wang N,Yang Y,Xiao B.A serum exosomal microRNA panel as a potential biomarker test for gastric cancer..Biochem Biophys Res Commun2017;493:1322-8

[71] Wang Q,Li A,Wang H.Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma..J Exp Clin Cancer Res2012;31:97 PMCID:PMC3554474

[72] Qu S,Liu Y.Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles..J Neurol Sci2015;348:181-7

[73] van der Vos KE,Zhang X,Carrizosa E.Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain..Neuro Oncol2016;18:58-69 PMCID:PMC4677420

[74] Akers JC,Li H,Yang Z.A cerebrospinal fluid microRNA signature as biomarker for glioblastoma..Oncotarget2017;8:68769-79 PMCID:PMC5620295

[75] Wang J,Zhang J.Cell-free microRNAs as non-invasive biomarkers in glioma: a diagnostic meta-analysis..Int J Biol Markers2019;34:232-42

[76] Saffroy R,Reffas M,Lemoine A.New perspectives and strategy research biomarkers for hepatocellular carcinoma..Clin Chem Lab Med2007;45:1169-79

[77] Mokdad AA,Singal AG.Management of hepatocellular in the United States..Chin Clin Oncol2017;6:21

[78] Bai X,Shao X,Dong E.The heterogeneity of plasma miRNA profiles in hepatocellular carcinoma patients and the exploration of diagnostic circulating miRNAs for hepatocellular carcinoma..PLoS One2019;14:e0211581 PMCID:PMC6363174

[79] Zhou J,Gao X,Wang J.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma..J Clin Oncol2011;29:4781-8

[80] Xu J,Che X,Yu D.Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis..Mol Carcinog2011;50:136-42

[81] Qu J,Chen M,Wang T.MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis..Pak J Med Sci2019;35:1466-71 PMCID:PMC6717466

[82] Qi P,Wang H,Chen YF.Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection..PLoS One2011;6:e28486 PMCID:PMC3234251

[83] Tan Y,Pan T,Chen L.A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus..PLoS One2014;9:e107986 PMCID:PMC4169601

[84] Li J,Yu W,Luo J.Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance..Biochem Biophys Res Commun2011;406:70-3

[85] Jin Y,Goh BKP,Cheow PC.Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma..Sci Rep2019;9:10464 PMCID:PMC6639394

[86] Ning S,Gao B,Yang A.miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma..Oncol Lett2019;18:3381-7 PMCID:PMC6676662

[87] Teufel M,Kochert K,Finn RS.Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma..Gastroenterology2019;156:1731-41

[88] Lindeman NI,Beasley MB,Dacic S.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology..J Mol Diagn2013;15:415-53

[89] Fiorentino FP,Miranda F,Russo A.CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer..Mol Cancer Res2011;9:225-33

[90] Yu Y,Tan Q,Li P.Plasma miR-92a-2 as a biomarker for small cell lung cancer..Cancer Biomark2017;18:319-27

[91] Shi GL,Sun Y,Song CX.Significance of serum microRNAs in the auxiliary diagnosis of non-small cell lung cancer..Clin Lab2017;63:133-40

[92] Heegaard NH,Welsh JA,Bowman ED.Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer..Int J Cancer2012;130:1378-86 PMCID:PMC3259258

[93] Zhang Y,Yin Y.Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients..Pathol Res Pract2019;215:152466

[94] Zheng D,Wang Y,Perry MC.Plasma microRNAs as novel biomarkers for early detection of lung cancer..Int J Clin Exp Pathol2011;4:575-86 PMCID:PMC3160609

[95] Giallombardo M,Castiglia M,Mertens I.Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) Patients’ Plasma through qPCR: a feasible liquid biopsy tool..J Vis Exp2016; PMCID:PMC4927740

[96] Jin X,Chen H,Chen D.Evaluation of tumor-derived exosomal mirna as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing..Clin Cancer Res2017;23:5311-9

[97] Zhou Y.MiR-520f acts as a biomarker for the diagnosis of lung cancer..Medicine (Baltimore)2019;98:e16546 PMCID:PMC6708931

[98] Zhang YL,Zhu XB,Lu P.Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer..Eur Rev Med Pharmacol Sci2019;23:5251-9

[99] Li J,Liu Z.Clinical significance of serum miR-25 in non-small-cell lung cancer..Br J Biomed Sci2019;76:111-6

[100] Bianchi F,Marzi M,Dall’olio V.A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer..EMBO Mol Med2011;3:495-503 PMCID:PMC3377091

[101] Balch CM,Soong SJ,Atkins MB.Final version of 2009 AJCC melanoma staging and classification..J Clin Oncol2009;27:6199-206 PMCID:PMC2793035

[102] Alegre E,Fernandez-Landazuri S,Gonzalez A.Circulating biomarkers in malignant melanoma..Adv Clin Chem2015;69:47-89

[103] Vereecken P,Van Baren N,Baurain JF.A synopsis of serum biomarkers in cutaneous melanoma patients..Dermatol Res Pract2012;2012:260643 PMCID:PMC3263591

[104] Solé C,Schramm M,Armesto M.The circulating transcriptome as a source of biomarkers for melanoma..Cancers (Basel)2019;11: PMCID:PMC6356785

[105] Shiiyama R,Jinnin M,Miyashita A.Sensitive detection of melanoma metastasis using circulating microRNA expression profiles..Melanoma Res2013;23:366-72

[106] Fogli S,Carpi S,Naccarati A.Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma..Tumour Biol2017;39:1010428317701646

[107] Greenberg E,Ben-Ami E,Itzhaki O.A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study..Biomarkers2013;18:502-8

[108] Alegre E,Rodriguez C,Martin-Algarra S.Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma..Arch Pathol Lab Med2014;138:828-32

[109] Tengda L,Mingli G,Yun L.Serum exosomal microRNAs as potent circulating biomarkers for melanoma..Melanoma Res2018;28:295-303

[110] Fleming NH,da Silva IP,Brady B.Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients..Cancer2015;121:51-9 PMCID:PMC4270907

[111] Tian R,Qiao L,Li J.Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma..Int J Clin Exp Pathol2015;8:3097-103 PMCID:PMC4440132

[112] Stark MS,Weide B,Pflugfelder A.The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis..EBioMedicine2015;2:671-80 PMCID:PMC4534690

[113] Van Laar R,Van Laar B.Development and validation of a plasma-based melanoma biomarker suitable for clinical use..Br J Cancer2018;118:857-66 PMCID:PMC5886119

[114] Svedman FC,Bottai M,Sonkoly E.Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma..PLoS One2018;13:e0206942 PMCID:PMC6219796

[115] Zhang H,Liu X.MicroRNA profiling of plasma exosomes from patients with ovarian cancer using high-throughput sequencing..Oncol Lett2019;17:5601-7 PMCID:PMC6507395

[116] Kim S,Jeong JY,Jung SG.Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas..J Cancer2019;10:1958-67 PMCID:PMC6548168

[117] Taylor DD.MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer..Gynecol Oncol2008;110:13-21

[118] Gong L,Gao Y.Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis..Biomed Pharmacother2016;83:58-63

[119] Marton E,Penyige A,Hegedus L.Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer..J Biotechnol2019;297:58-65

[120] Wang W,Shan X,Liu P.The value of plasma-based microRNAs as diagnostic biomarkers for ovarian cancer..Am J Med Sci2019;358:256-67

[121] Ballehaninna UK.The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal..J Gastrointest Oncol2012;3:105-19 PMCID:PMC3397644

[122] Goggins M.Molecular markers of early pancreatic cancer..J Clin Oncol2005;23:4524-31

[123] Liu R,Du Y,Shen L.Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer..Clin Chem2012;58:610-8

[124] Nakamura S,Ohtsuka T,Nakashima Y.Pancreatic juice exosomal microRNAs as biomarkers for detection of pancreatic ductal adenocarcinoma..Ann Surg Oncol2019;26:2104-11

[125] Vila-Navarro E,Vila-Casadesus M,Gines A.Novel circulating miRNA signatures for early detection of pancreatic neoplasia..Clin Transl Gastroenterol2019;10:e00029 PMCID:PMC6602779

[126] Zhu Y,Wang F,Liu G.Differential microRNA expression profiles as potential biomarkers for pancreatic ductal adenocarcinoma..Biochemistry (Mosc)2019;84:575-82

[127] Kelly BD,Sweeney KJ,Rogers E.A circulating microRNA signature as a biomarker for prostate cancer in a high risk group..J Clin Med2015;4:1369-79 PMCID:PMC4519795

[128] Matin F,Moya L,Chambers S.A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer..Sci Rep2018;8:6653 PMCID:PMC5923293

[129] Mahn R,Rogenhofer S,Muller SC.Circulating microRNAs (miRNA) in serum of patients with prostate cancer..Urology2011;77:1265.e9-16

[130] Brase JC,Schlomm T,Haese A.Circulating miRNAs are correlated with tumor progression in prostate cancer..Int J Cancer2011;128:608-16

[131] Al-Qatati A,Stevic I,Awe J.Plasma microRNA signature is associated with risk stratification in prostate cancer patients..Int J Cancer2017;141:1231-9

[132] Shen J,McKiernan JM,Lipsky MJ.Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer..Prostate2012;72:1469-77 PMCID:PMC3368098

[133] Sharova E,Marcer A,Pinto F.A circulating miRNA assay as a first-line test for prostate cancer screening..Br J Cancer2016;114:1362-6 PMCID:PMC4984473

[134] Cochetti G,Guelfi G,Egidi MG.Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role..Onco Targets Ther2016;9:7545-53 PMCID:PMC5167485

[135] Huang X,Liang M,Xia S.Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer..Eur Urol2015;67:33-41 PMCID:PMC4252606

[136] Hoey C,Fotouhi Ghiam A,Huang X.Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy..J Transl Med2019;17:173 PMCID:PMC6533745

[137] Moltzahn F,Baehner L,Fong L.Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients..Cancer Res2011;71:550-60 PMCID:PMC3022112

[138] Zhang HL,Zhu Y,Zhang SL.Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy..Prostate2011;71:326-31

[139] Lin HM,Mahon KL,Lee BY.Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer..Br J Cancer2014;110:2462-71 PMCID:PMC4021524

[140] Dohner H,Bloomfield CD.Acute myeloid leukemia..N Engl J Med2015;373:1136-52

[141] De Kouchkovsky I.Acute myeloid leukemia: a comprehensive review and 2016 update..Blood Cancer J2016;6:e441 PMCID:PMC5030376

[142] Prada-Arismendy J,Rothlisberger S.Molecular biomarkers in acute myeloid leukemia..Blood Rev2017;31:63-76

[143] Zhi F,Xie X,Dong W.Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia..PLoS One2013;8:e56718 PMCID:PMC3577716

[144] Fayyad-Kazan H,Najar M,Fayyad-Kazan M.Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia..J Transl Med2013;11:31 PMCID:PMC3579719

[145] Zhi Y,Wang R,Gu W.Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia..Int J Hematol2015;102:296-303

[146] Tang X,Yan X,Xiong Y.Overexpression of miR-210 is associated with poor prognosis of acute myeloid leukemia..Med Sci Monit2015;21:3427-33 PMCID:PMC4644019

[147] Marcucci G,Metzeler KH,Wu YZ.Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients..J Clin Oncol2013;31:2086-93 PMCID:PMC3731981

[148] Fang Z,Wu J,Liu J.High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia..Cancer Biomark2019;27:1-9

[149] Guo Y.Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia..Bioengineered2019;10:345-52 PMCID:PMC6738448

[150] Jabber Al-Obaidi MS,Bennett CF,Goldstone AH.ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia..Leukemia2002;16:669-74

[151] Moorman AV.The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia..Blood Rev2012;26:123-35

[152] Luna-Aguirre CM,Mar-Aguilar F,Trevino-Alvarado V.Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia..Cancer Biomark2015;15:299-310

[153] Ishihara K,Tsuruda K,Nagai K.Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia..Cancer Epidemiol2012;36:560-5

[154] Swellam M,Mahmoud MS,Hassan NM.Aberrant expression of some circulating miRNAs in childhood acute lymphoblastic leukemia..Biochem Genet2018;56:283-94

[155] Amaya-Chanaga CI.Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers..Best Pract Res Clin Haematol2016;29:79-89

[156] Ferrajoli A,Ivan C,Rabe KG.Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia..Blood2013;122:1891-9 PMCID:PMC3779381

[157] Yeh YY,Lehman AM,Yu L.Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling..Blood2015;125:3297-305 PMCID:PMC4440883

[158] Stamatopoulos B,Crompot E,Housni HE.Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia..Mol Med2015;21:123-33 PMCID:PMC4461585

[159] Marcucci G,Radmacher MD,Croce CM.MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias..Best Pract Res Clin Haematol2009;22:239-48

[160] Skrabek P,Seftel M.Epidemiology of non-Hodgkin lymphoma..Transfus Apher Sci2013;49:133-8

[161] Morra E.The biological markers of non-Hodgkin’s lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy..Int J Biol Markers1999;14:149-53

[162] Fang C,Dong HJ,Wang YH.Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma..Ann Hematol2012;91:553-9

[163] Yuan WX,Na WN,Yang X.Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients..Oncol Lett2016;11:423-32 PMCID:PMC4726930

[164] Jones CI,King AJ,Horne GA.Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma..Br J Cancer2012;107:1987-96 PMCID:PMC3516695

[165] Yoshizawa S,Ohyashiki M,Suzuki K.Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders..Blood Cancer J2012;2:e53 PMCID:PMC3270255

[166] Huang JJ,Li JY,Zhong RQ.Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma..Med Oncol2012;29:2402-8

[167] Sevcikova S,Sedlarikova L,Hajek R.Serum miR-29a as a marker of multiple myeloma..Leuk Lymphoma2013;54:189-91

[168] Kubiczkova L,Slaby O,Jarkovsky J.Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance..Haematologica2014;99:511-8 PMCID:PMC3943315

[169] Rocci A,Geyer S,Gambella M.Circulating miRNA markers show promise as new prognosticators for multiple myeloma..Leukemia2014;28:1922-6 PMCID:PMC4155011

[170] Qu X,Wu S,Xu J.Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma..Med Oncol2014;31:219

[171] Hao M,Zhao L,Xu Y.Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis..Oncotarget2016;7:19589-600 PMCID:PMC4991403

[172] Hao M,Wendlandt E,An G.Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma..Int J Cancer2015;136:1835-44 PMCID:PMC4382914

[173] Jung SH,Lee M,Yim SH.Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma..Haematologica2017;102:e456-e9 PMCID:PMC5664408

[174] Navarro A,Tovar N,Tejero R.A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma..Oncotarget2015;6:1874-83 PMCID:PMC4359338

[175] Besse L,Kryukov F,Radova L.Circulating serum microRNA-130a as a novel putative marker of extramedullary myeloma..PLoS One2015;10:e0137294 PMCID:PMC4577078

[176] Pardini B,Birolo G.Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies..Cancers (Basel)2019;11: PMCID:PMC6721601